Immix Biopharma, Inc. (Nasdaq:IMMX)

Immix Biopharma, Inc. (Nasdaq:IMMX)

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

Format

PNG

Source

Immix Biopharma, Inc.

Téléchargements